255 related articles for article (PubMed ID: 29115542)
21. Calretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples.
Lugli A; Forster Y; Haas P; Nocito A; Bucher C; Bissig H; Mirlacher M; Storz M; Mihatsch MJ; Sauter G
Hum Pathol; 2003 Oct; 34(10):994-1000. PubMed ID: 14608532
[TBL] [Abstract][Full Text] [Related]
22. An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia.
Lu D; Vohra P; Chu PG; Woda B; Rock KL; Jiang Z
Am J Surg Pathol; 2009 Apr; 33(4):521-5. PubMed ID: 19047899
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer.
Hsu KF; Shen MR; Huang YF; Cheng YM; Lin SH; Chow NH; Cheng SW; Chou CY; Ho CL
Br J Cancer; 2015 Jul; 113(3):414-24. PubMed ID: 26158423
[TBL] [Abstract][Full Text] [Related]
24. Insulin-like growth factor 2 mRNA-binding protein-3 as a marker for distinguishing between cutaneous squamous cell carcinoma and keratoacanthoma.
Kanzaki A; Kudo M; Ansai S; Peng WX; Ishino K; Yamamoto T; Wada R; Fujii T; Teduka K; Kawahara K; Kawamoto Y; Kitamura T; Kawana S; Saeki H; Naito Z
Int J Oncol; 2016 Mar; 48(3):1007-15. PubMed ID: 26782292
[TBL] [Abstract][Full Text] [Related]
25. Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome.
Grupp K; Hofmann B; Kutup A; Bachmann K; Bogoevski D; Melling N; Uzunoglu FG; El Gammal AT; Koop C; Simon R; Steurer S; Krech T; Burdak-Rothkamm S; Jacobsen F; Sauter G; Izbicki J; Wilczak W
BMC Cancer; 2018 Nov; 18(1):1106. PubMed ID: 30419865
[TBL] [Abstract][Full Text] [Related]
26. Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder.
Xylinas E; Cha EK; Khani F; Kluth LA; Rieken M; Volkmer BG; Hautmann R; Küfer R; Chen YT; Zerbib M; Rubin MA; Scherr DS; Shariat SF; Robinson BD
J Urol; 2014 Mar; 191(3):830-41. PubMed ID: 23994370
[TBL] [Abstract][Full Text] [Related]
27. The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors.
Hudlebusch HR; Santoni-Rugiu E; Simon R; Ralfkiær E; Rossing HH; Johansen JV; Jørgensen M; Sauter G; Helin K
Clin Cancer Res; 2011 May; 17(9):2919-33. PubMed ID: 21385930
[TBL] [Abstract][Full Text] [Related]
28. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.
Walter O; Prasad M; Lu S; Quinlan RM; Edmiston KL; Khan A
Hum Pathol; 2009 Nov; 40(11):1528-33. PubMed ID: 19695680
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
[TBL] [Abstract][Full Text] [Related]
30. Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer.
Findeis-Hosey JJ; Xu H
Biotech Histochem; 2012 Jan; 87(1):24-9. PubMed ID: 21838610
[TBL] [Abstract][Full Text] [Related]
31. Insulin-like growth factor II messenger RNA-binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm.
Morimatsu K; Aishima S; Yamamoto H; Hayashi A; Nakata K; Oda Y; Shindo K; Fujino M; Tanaka M; Oda Y
Hum Pathol; 2013 Sep; 44(9):1714-21. PubMed ID: 23597774
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological Implication of Insulin-like Growth Factor-II mRNA-Binding Protein 3 (IMP3) Expression in Gastric Cancer.
Lee D; Yu EJ; Ham IH; Hur H
Anticancer Res; 2017 Jan; 37(1):135-142. PubMed ID: 28011483
[TBL] [Abstract][Full Text] [Related]
33. IMP2/IGF2BP2 expression, but not IMP1 and IMP3, predicts poor outcome in patients and high tumor growth rate in xenograft models of gallbladder cancer.
Kessler SM; Lederer E; Laggai S; Golob-Schwarzl N; Hosseini K; Petzold J; Schweiger C; Reihs R; Keil M; Hoffmann J; Mayr C; Kiesslich T; Pichler M; Kim KS; Rhee H; Park YN; Lax S; Obrist P; Kiemer AK; Haybaeck J
Oncotarget; 2017 Oct; 8(52):89736-89745. PubMed ID: 29163784
[TBL] [Abstract][Full Text] [Related]
34. Insulin-like growth factor II messenger RNA-binding protein-3 is an indicator of malignant phyllodes tumor of the breast.
Takizawa K; Yamamoto H; Taguchi K; Ohno S; Tokunaga E; Yamashita N; Kubo M; Nakamura M; Oda Y
Hum Pathol; 2016 Sep; 55():30-8. PubMed ID: 27137988
[TBL] [Abstract][Full Text] [Related]
35. Expression of insulin-like growth factor II mRNA-binding protein 3 in human esophageal adenocarcinoma and its precursor lesions.
Feng W; Zhou Z; Peters JH; Khoury T; Zhai Q; Wei Q; Truong CD; Song SW; Tan D
Arch Pathol Lab Med; 2011 Aug; 135(8):1024-31. PubMed ID: 21809994
[TBL] [Abstract][Full Text] [Related]
36. IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG.
Samanta S; Sun H; Goel HL; Pursell B; Chang C; Khan A; Greiner DL; Cao S; Lim E; Shultz LD; Mercurio AM
Oncogene; 2016 Mar; 35(9):1111-21. PubMed ID: 25982283
[TBL] [Abstract][Full Text] [Related]
37. IMP3, a proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast.
Vranic S; Gurjeva O; Frkovic-Grazio S; Palazzo J; Tawfik O; Gatalica Z
Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):413-6. PubMed ID: 21436679
[TBL] [Abstract][Full Text] [Related]
38. IMP3 Expression in Borderline Tumors of the Ovary.
El-Balat A; Sänger N; Karn T; Becker S; Holtrich U; Muallem Z; Arsenic R
Anticancer Res; 2017 Feb; 37(2):583-588. PubMed ID: 28179304
[TBL] [Abstract][Full Text] [Related]
39. IMP3 is a novel biomarker to predict metastasis and prognosis of tongue squamous cell carcinoma.
Li HG; Han JJ; Huang ZQ; Wang L; Chen WL; Shen XM
J Craniofac Surg; 2011 Nov; 22(6):2022-5. PubMed ID: 22067851
[TBL] [Abstract][Full Text] [Related]
40. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder.
Sitnikova L; Mendese G; Liu Q; Woda BA; Lu D; Dresser K; Mohanty S; Rock KL; Jiang Z
Clin Cancer Res; 2008 Mar; 14(6):1701-6. PubMed ID: 18347170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
